Gins4

Gins4 Full Name

GINS complex subunit 4 (Sld5 homolog)

Gins4 Introduction

GINS complex subunit 4 (GINS4), also known as Sld5 homolog, is a core component of the highly conserved GINS complex, which plays an essential role in DNA replication initiation and elongation. For researchers and clinicians working on proliferative diseases, understanding GINS4 is particularly important because it sits at the heart of the replication machinery—forming the CMG helicase complex together with CDC45 and the MCM2–7 complex. This complex unwinds DNA at replication forks, ensuring accurate genome duplication during the S phase of the cell cycle. Dysregulation of such a fundamental process often leads to genomic instability, a hallmark of cancer and other proliferative disorders, making GINS4 an increasingly relevant molecular target in both basic research and drug discovery.

Functionally, GINS4 is not only a structural component but also a regulatory factor influencing cell cycle progression, DNA replication fidelity, and cell fate decisions. Experimental studies have shown that GINS4 overexpression enhances cell proliferation, promotes G1/S phase transition, and suppresses apoptosis, particularly in rapidly dividing tumor cells. Mechanistically, it can be transcriptionally repressed by tumor suppressors such as KLF4, while its upregulation contributes to oncogenic signaling pathways. More recent findings expand its functional landscape beyond replication: GINS4 has been implicated in the regulation of ferroptosis, where it suppresses p53 acetylation through interaction with EMT-related transcription factors like Snail, thereby reducing ferroptotic sensitivity in cancer cells. These insights highlight a key pain point in oncology—treatment resistance—by revealing how replication-associated proteins like GINS4 can influence non-apoptotic cell death pathways.

Clinically, GINS4 has emerged as a promising biomarker and potential therapeutic target across multiple disease contexts. In colorectal cancer, its elevated expression correlates with advanced tumor stage, poor differentiation, and unfavorable prognosis, suggesting strong diagnostic and prognostic value. Similarly, in lung adenocarcinoma and breast cancer, GINS4 contributes to tumor growth, metastasis, and therapy resistance through complex regulatory networks, including circRNA–miRNA axes. Beyond oncology, loss-of-function mutations in GINS4 have been linked to primary immunodeficiency characterized by natural killer (NK) cell deficiency and neutropenia, underscoring its essential role in immune cell development. This dual relevance in both cancer progression and immune dysfunction makes GINS4 a compelling target for translational research, especially for those seeking novel strategies to overcome drug resistance or to develop precision medicine approaches.

Alternate Names for Gins4

GINS4; GINS complex subunit 4 (Sld5 homolog); SLD5; DNA replication complex GINS protein SLD5; SLD5 homolog;

• 1.Rong Z, et al.; GINS complex subunit 4, a prognostic biomarker and reversely mediated by Krüppel-like factor 4, promotes the growth of colorectal cancer. Cancer Sci. 2020, 111(4):1203-1217.
  2.Conte MI, et al.; Partial loss-of-function mutations in GINS4 lead to NK cell deficiency with neutropenia. JCI Insight. 2022, 7(21):e154948.